-
Mashup Score: 0
PURPOSE To report clinical and treatment characteristics, remission and failure patterns, and risk factors for local failure (LF) from the EMBRACE-I study. MATERIALS AND METHODS EMBRACE-I was a prospective, observational, multicenter cohort study on magnetic resonance imaging–based image-guided adaptive brachytherapy (MR-IGABT) in locally advanced cervical cancer. Treatment consisted of external…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5IJGC Journal Club - 3 year(s) ago
Join us Friday, November 18 for November Journal Club! The lead article is: Safety of ovarian preservation for premenopausal patients with FIGO Stage I grade 2 and 3 endometrioid endometrial adenocarcinoma by Dimitrios Nasioudis
Source: IGCSCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @IGCSociety: Join us TOMORROW, November 18th for November Journal Club! More info: https://t.co/SKNN0m6Ar9 https://t.co/cFeU4rsf73
-
-
Mashup Score: 1
Partnering with a psychiatrist coach could lead some physicians to question the exact nature of the service being offered. For this reason, each coaching client signs a coaching agreement defining the relationship between coach and client and clarifying that boundary.
Source: KevinMD.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @kevinmd: Coaching vs. therapy: A physician coach and psychiatrist explains https://t.co/MOapW9nQfK #Physician #Psychiatry via @kevinmd
-
-
Mashup Score: 2Recurrence - Reducing your Risk , Making Treatment Decisions - 3 year(s) ago
On Wednesday, November 9, 2022 at 8pm ET (7pm CT, 5pm PT) the #gyncsm community will chat about Recurrence in Gynecologic Cancers. We wi…
Source: gyncsm.blogspot.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @gyncsm: #gyncsm Community: Here's the information about our next chat Wed Nov 9th at 8pmET on Recurrence. https://t.co/kDGQE4ozGp https…
-
-
Mashup Score: 2BRCA Mutations, HRD Status Drive PARP Inhibitor Selection in Ovarian Cancer Maintenance - 3 year(s) ago
Bobbie J. Rimel, MD, discusses how PARP inhibitors are deployed across different treatment settings of ovarian cancer, the recent market withdrawal of PARP inhibitors in later-line indications, and ongoing research efforts at Cedars-Sinai Medical Center for patients with ovarian cancer.
Source: OncLiveCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @womenofteal: BRCA Mutations, HRD Status Drive PARP Inhibitor Selection in Ovarian Cancer Maintenance https://t.co/8QCeAUmZd5 #gyncsm
-
-
Mashup Score: 3Validity of the COmprehensive Score for financial Toxicity (COST) in patients with gynecologic cancer - 3 year(s) ago
Objective Financial toxicity is a financial burden of cancer care itself, which leads to worse quality of life and higher mortality and is considered an adverse effect. The COmprehensive Score for financial Toxicity (COST) tool is a patient-reported outcome measurement used to evaluate financial toxicity. We aimed to validate the internal consistency and reproducibility of the COST tool in…
Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @IJGConline: "Validity of the COmprehensive Score for financial Toxicity (COST) in patients with #GynCancer" https://t.co/gIDMAum0i7 @G…
-
-
Mashup Score: 1Your November Net Connection - 3 year(s) ago
View this email in your browser Our Stories | Volunteer | Our Work | Donate November, 2022 Dear friends, The fall has been busy and just gets busier. This month we have many exciting developments, inc
Source: Health Volunteers OverseasCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @HVOUSA: Don't miss HVO's November Net Connection! https://t.co/bGlXHPbg9l https://t.co/0uGWGc1BTV
-
-
Mashup Score: 11#gyncsm Community - 3 year(s) ago
A community for those impacted by gynecologic cancer. | Est. 2013
Source: gyncsm.blogspot.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @gyncsm: Join/Share: #GynCSM (Gynecologic Cancer Social Media) tweet chat Wed Nov 9th at 8pmET https://t.co/nDbbZnerzF https://t.co/cuK2…
-
-
Mashup Score: 4September 14, 2022 Clinical Trials: When, How and For Whom - 3 year(s) ago
There is always so much to discuss about Clinical Trials and this month we concentrated on who should consider a trial, how to finding trial…
Source: gyncsm.blogspot.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @gyncsm: Miss last month's #gyncsm chat on #ClinicalTrials? Here's the recap and resource links: https://t.co/0ndYwwP5mQ #cervicalcance…
-
-
Mashup Score: 0New study questions the effectiveness of colonoscopies — CNN - 3 year(s) ago
A “landmark” study suggests the benefits of colonoscopies for cancer screening may be overestimated.
Source: apple.newsCategories: Hem/Oncs, Latest HeadlinesTweet-
New study questions the effectiveness of #colonoscopies - CNN. Only 42% in the study group did the #colonoscopy https://t.co/LRhcaGWWis
-
Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image–Guided Brachytherapy in Locally Advanced Cervical Cancer: 95% LC 3 years postintervention for squamous cell in comparison to 86% for adeno/adenosquamous #cervicalcancer https://t.co/raQi1LoesZ